GSK 6-K
GSK plc (GSK)
6-K
2026-02-17
For: 2026-02-17
View Original
Added on
July 04, 2026
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of February 2026
Commission File Number 001-15170
GSK plc
(Translation of registrant's name into English)
79 New Oxford Street, London, WC1A 1DG
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F . . . .X. . . . Form 40-F . . . . . . . .
GSK plc (the 'Company')
Deferred Annual Bonus Plan Awards
On 12 February 2026, the Company granted awards to the Persons Discharging Managerial Responsibilities ('PDMRs') listed below. The awards have been granted in accordance with the rules of the GlaxoSmithKline 2017 Deferred Annual Bonus Plan ('DABP') which was approved by shareholders on 4 May 2017.
Executive Directors and other members of the Executive Committee are required to defer part of any bonus earned into Ordinary Shares or American Depositary Shares ('ADS') for three years. Under the terms of the Remuneration Policy approved by shareholders in 2025, Executive Directors are required to defer 50% of bonus equivalent to the first 200% of salary into Ordinary Shares or ADS with any portion in excess of 200% being deferred in full. Other members of the Executive Committee are required to defer 25% of bonus equivalent to the first 170% of salary into Ordinary Shares or ADS with any portion in excess of 170% being deferred in full.
The awards have been granted as restricted awards over ADS for US participants and as nil-cost options over Ordinary Shares for all other participants.
The numbers of Ordinary Shares and ADS shown below are exclusive of dividend reinvestment that will accrue during the deferral period.
The notifications that follow are for awards made to Executive Directors and members of the Executive Committee who served on that Committee during the year ended 31 December 2025.
Transaction notification
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | ||||
|---|---|---|---|---|---|
| a) | Name | Luke Miels | |||
| b) | Position/status | Chief Executive Officer | |||
| c) | Initial<br>notification/<br><br>amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | ||||
| a) | Description<br>of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br>ISIN: GB00BN7SWP63 | |||
| b) | Nature<br>of the transaction | Deferred Bonus Award of Ordinary Shares under the GlaxoSmithKline<br>2017 Deferred Annual Bonus Plan | |||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | ||
| £21.50 | 27,962 | ||||
| d) | Aggregated<br>information | N/A (single transaction) | |||
| Aggregated<br>volume Price | |||||
| e) | Date<br>of the transaction | 2026-02-12 | |||
| f) | Place<br>of the transaction | N/A | |||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | ||||
| --- | --- | --- | --- | --- | --- |
| a) | Name | Julie Brown | |||
| b) | Position/status | Chief Financial Officer | |||
| c) | Initial<br>notification/<br><br>amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | ||||
| a) | Description<br>of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br>ISIN: GB00BN7SWP63 | |||
| b) | Nature<br>of the transaction | Deferred Bonus Award of Ordinary Shares under the GlaxoSmithKline<br>2017 Deferred Annual Bonus Plan | |||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | ||
| £21.50 | 55,178 | ||||
| d) | Aggregated<br>information | N/A (single transaction) | |||
| Aggregated<br>volume Price | |||||
| e) | Date<br>of the transaction | 2026-02-12 | |||
| f) | Place<br>of the transaction | N/A | |||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | ||||
| --- | --- | --- | --- | --- | --- |
| a) | Name | Diana Conrad | |||
| b) | Position/status | Chief People Officer | |||
| c) | Initial<br>notification/<br><br>amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | ||||
| a) | Description<br>of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br>ISIN: GB00BN7SWP63 | |||
| b) | Nature<br>of the transaction | Deferred Bonus Award of Ordinary Shares under the GlaxoSmithKline<br>2017 Deferred Annual Bonus Plan | |||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | ||
| £21.50 | 15,984 | ||||
| d) | Aggregated<br>information | N/A (single transaction) | |||
| Aggregated<br>volume Price | |||||
| e) | Date<br>of the transaction | 2026-02-12 | |||
| f) | Place<br>of the transaction | N/A | |||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | ||||
| --- | --- | --- | --- | --- | --- |
| a) | Name | James Ford | |||
| b) | Position/status | SVP and Group General Counsel, Legal and Compliance | |||
| c) | Initial<br>notification/<br><br>amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | ||||
| a) | Description<br>of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br>ISIN: GB00BN7SWP63 | |||
| b) | Nature<br>of the transaction | Deferred Bonus Award of Ordinary Shares under the GlaxoSmithKline<br>2017 Deferred Annual Bonus Plan | |||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | ||
| £21.50 | 13,229 | ||||
| d) | Aggregated<br>information | N/A (single transaction) | |||
| Aggregated<br>volume Price | |||||
| e) | Date<br>of the transaction | 2026-02-12 | |||
| f) | Place<br>of the transaction | N/A | |||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | ||||
| --- | --- | --- | --- | --- | --- |
| a) | Name | Shobie Ramakrishnan | |||
| b) | Position/status | Chief Digital and Technology Officer | |||
| c) | Initial<br>notification/<br><br>amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | ||||
| a) | Description<br>of the financial instrument | American Depositary Shares ('ADS')<br><br><br>ISIN: US37733W2044 | |||
| b) | Nature<br>of the transaction | Deferred Bonus Award of ADS under the GlaxoSmithKline 2017 Deferred<br>Annual Bonus Plan | |||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | ||
| $58.49 | 6,557 | ||||
| d) | Aggregated<br>information | N/A (single transaction) | |||
| Aggregated<br>volume Price | |||||
| e) | Date<br>of the transaction | 2026-02-12 | |||
| f) | Place<br>of the transaction | N/A | |||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | ||||
| --- | --- | --- | --- | --- | --- |
| a) | Name | David Redfern | |||
| b) | Position/status | President, Corporate Development | |||
| c) | Initial<br>notification/<br><br>amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | ||||
| a) | Description<br>of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br>ISIN: GB00BN7SWP63 | |||
| b) | Nature<br>of the transaction | Deferred Bonus Award of Ordinary Shares under the GlaxoSmithKline<br>2017 Deferred Annual Bonus Plan | |||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | ||
| £21.50 | 19,494 | ||||
| d) | Aggregated<br>information | N/A (single transaction) | |||
| Aggregated<br>volume Price | |||||
| e) | Date<br>of the transaction | 2026-02-12 | |||
| f) | Place<br>of the transaction | N/A | |||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | ||||
| --- | --- | --- | --- | --- | --- |
| a) | Name | Regis Simard | |||
| b) | Position/status | President, Global Supply Chain | |||
| c) | Initial<br>notification/<br><br>amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | ||||
| a) | Description<br>of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br>ISIN: GB00BN7SWP63 | |||
| b) | Nature<br>of the transaction | Deferred Bonus Award of Ordinary Shares under the GlaxoSmithKline<br>2017 Deferred Annual Bonus Plan | |||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | ||
| £21.50 | 20,427 | ||||
| d) | Aggregated<br>information | N/A (single transaction) | |||
| Aggregated<br>volume Price | |||||
| e) | Date<br>of the transaction | 2026-02-12 | |||
| f) | Place<br>of the transaction | N/A | |||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | ||||
| --- | --- | --- | --- | --- | --- |
| a) | Name | Phil Thomson | |||
| b) | Position/status | President, Global Affairs | |||
| c) | Initial<br>notification/<br><br>amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | ||||
| a) | Description<br>of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br>ISIN: GB00BN7SWP63 | |||
| b) | Nature<br>of the transaction | Deferred Bonus Award of Ordinary Shares under the GlaxoSmithKline<br>2017 Deferred Annual Bonus Plan | |||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | ||
| £21.50 | 14,167 | ||||
| d) | Aggregated<br>information | N/A (single transaction) | |||
| Aggregated<br>volume Price | |||||
| e) | Date<br>of the transaction | 2026-02-12 | |||
| f) | Place<br>of the transaction | N/A | |||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | ||||
| --- | --- | --- | --- | --- | --- |
| a) | Name | Deborah Waterhouse | |||
| b) | Position/status | CEO, ViiV Healthcare and President, Global Health, GSK | |||
| c) | Initial<br>notification/<br><br>amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | ||||
| a) | Description<br>of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br>ISIN: GB00BN7SWP63 | |||
| b) | Nature<br>of the transaction | Deferred Bonus Award of Ordinary Shares under the GlaxoSmithKline<br>2017 Deferred Annual Bonus Plan | |||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | ||
| £21.50 | 18,543 | ||||
| d) | Aggregated<br>information | N/A (single transaction) | |||
| Aggregated<br>volume Price | |||||
| e) | Date<br>of the transaction | 2026-02-12 | |||
| f) | Place<br>of the transaction | N/A | |||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | ||||
| --- | --- | --- | --- | --- | --- |
| a) | Name | Tony Wood | |||
| b) | Position/status | Chief Scientific Officer | |||
| c) | Initial<br>notification/<br><br>amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | ||||
| a) | Description<br>of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br>ISIN: GB00BN7SWP63 | |||
| b) | Nature<br>of the transaction | Deferred Bonus Award of Ordinary Shares under the GlaxoSmithKline<br>2017 Deferred Annual Bonus Plan | |||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | ||
| £21.50 | 25,915 | ||||
| d) | Aggregated<br>information | N/A (single transaction) | |||
| Aggregated<br>volume Price | |||||
| e) | Date<br>of the transaction | 2026-02-12 | |||
| f) | Place<br>of the transaction | N/A |
About GSK
GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.
Registered in England & Wales:
No. 3888792
Registered Office:
79 New Oxford Street
London
WC1A 1DG
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.
| GSK plc | |
|---|---|
| (Registrant) | |
| Date: February<br>16, 2026 | |
| By:/s/ VICTORIA<br>WHYTE<br><br>-------------------------- | |
| Victoria Whyte | |
| Authorised<br>Signatory for and on | |
| behalf<br>of GSK plc |